Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RhoVac AB
Lund, Swedenchosaoncology.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
The company’s lead drug candidate RV001 has completed clinical phase I/II and entered clinical phase IIb development. It aims to stimulate the immune system to identify and destroy cells that over-express a certain protein linked to cancer progression. The approach involves peptide-based immunotherapy designed as a therapeutic cancer vaccine with potential effects on metastasis prevention or limitation[1][2][5].
- Therapeutic areas
- Oncology
- Modalities
- Peptide-based therapeutic cancer vaccine (immunotherapy)
- Industry
- Biotech
Beyond the preview
Go deeper on RhoVac AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RhoVac AB.